Quotes for Scandion Oncology
- +/-
- %
- ()
Board
CEO
- Bo Rode Hansen
Chairperson of the Board
- Peter Høngaard
Board
- Annie Rasmussen
- Bo Hansen
- Carl Borrebäck
- Christian Vinding Thomsen
- Jørgen Bardenfleth
- Thomas Feldthus
Scandion Oncology
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.
News
- Scandion Oncology adjusts the PANTAX pancreatic cancer study
- Scandion Oncology has finalized the first 12 patients in the CORIST study
- Spotlight: Market Notice 11/21 - Scandion Oncology A/S will be delisted after close of the market on February 2, 2021
- Scandion Oncology approved for listing on Nasdaq First North Growth Market Sweden on 3 February 2021
- Spotlight: Market Notice 5/21– Last day of trading in Scandion Oncology A/S’s BTA